logo-loader
viewValiRx PLC

ValiRx in talks to terminate subscription agreement and enter into a new convertible bond facility

The firm said its working capital position is dependent on new funds being made available to it and anticipates that the investor will provide it with additional funds under the new facility

Funding sign
ValiRx said the terms of the anticipated new facility are still subject to agreement and the it expects to notify details in due course

ValiRx Plc (LON:VAL) said it is now in advanced discussions with European High Growth Opportunities SF to terminate the entire subscription agreement that was announced on 26 April 2019, following a delay to the issue of the Tranche 2 shares, and enter into a new convertible bond facility with the investor. 

The group said the terms of the anticipated new facility are still subject to agreement and it expects to notify details in due course.

READ: ValiRx updates on second round of funding discussions

ValiRx said its working capital position is dependent on new funds being made available to it and anticipates that the investor will provide it with additional funds under the new facility as soon as the definitive legal documentation is entered into.

In the event that discussions with the investor terminate, however, the company said it will need to seek other sources of finance to meet its short term working capital requirements.

Quick facts: ValiRx PLC

Price: 0.125 GBX

AIM:VAL
Market: AIM
Market Cap: £1.67 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ValiRx PLC named herein, including the promotion by the Company of ValiRx PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: Green light for ValiRx to increase dose of VAL201

Top stories from the Proactive Investors UK newsroom. ValirX (LON:VAL) has received a boost for its prostate cancer treatment VAL201 after UK regulators approved a substantial increase in the doses allowed in future clinical trials. The phase I/II trial so far has met all primary and...

on 20/6/19

2 min read